Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing

---

PRESS RELEASE: Strategic Seed Investors Include Kite Pharma Founder, Arie Belldegrun, M.D., FACS, Chairman of Gilead Sciences, John Martin, Ph.D., Norbert Bischofberger, Ph.D., Omega Funds and Vida Ventures CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 23, 2018– Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced the…Read More